← 返回

超声力遗传学肿瘤预激用于 CAR-T 治疗

英文原题:Tumour priming by ultrasound mechanogenetics for CAR T therapy.

查看英文原题

Tumour priming by ultrasound mechanogenetics for CAR T therapy.

PubMed 2025/10/31(内容时间) Nat Mater Q1 · IF 38(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基于细胞的癌症免疫疗法具有治疗潜力,但用于实体瘤仍面临挑战。本文报告一种基于聚焦超声的方法,通过机械刺激在实体瘤内一部分细胞中局部诱导表达CD19抗原,这些细胞可作为局部“训练中心”激活CAR-T 细胞。活化后的CAR-T 细胞攻击肿瘤部位附近的整个癌细胞群,从而抑制癌症。该系统将聚焦超声触发的机械刺激及癌细胞随后产生的钙响应,与多西环素门控的AND逻辑基因回路相结合;两种信号均需激活,才能有效诱导CD19表达,从而实现靶向基因表达。研究者在体外、类器官及体内验证了该方法的功能,无需任何辅助因子,仅通过聚焦超声介导的机械刺激即可直接控制用户设计的基因表达,显示出该平台可用于精准可控免疫治疗的潜力。总体而言,这种组合方法通过诱导产生临床已验证的抗原,可利用聚焦超声远程、无创地预处理实体瘤,以实现有效且安全的CAR-T 细胞免疫治疗。

展开英文摘要原文

Cell-based cancer immunotherapy holds potential as a therapeutic approach, yet its application for solid tumour treatment remains challenging.

Here we report a focused-ultrasound-based approach that mechanically induces the localized expression of CD19 antigen within a subpopulation of cells within solid tumours, which function as local 'training centres' to activate chimeric antigen receptor T cells. Activated chimeric antigen receptor T cells attack the whole cancer cell population near the tumour site, thus achieving cancer suppression.

The system achieves targeted gene expression by integrating focused-ultrasound-triggered mechanical stimulation and the subsequent calcium response of cancer cells with a doxycycline-gated AND-logic genetic circuit, both of which need to be active for effective induction of CD19 expression.

We validate the functionality of the approach in vitro, in organoids and in vivo, achieving direct control of user-designed gene expressions through FUS-mediated mechanical stimulation without the need of any cofactor, demonstrating the approach's potential as a versatile platform for precisely controllable immunotherapy.

Overall, our combinatorial approach offers a focused-ultrasound-controlled remote and non-invasive priming of solid tumours for effective and safe chimeric antigen receptor T cell immunotherapy via the induced production of clinically validated antigens.

论文信息

作者
Yoon CW、Song C、Nguyen DNM、Yu X、Zhu L、Ho P、Huang Z、Lu G
第一作者单位
The Shu Chien-Gene Lay Department of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA, USA. soulishguy@gmail.com.United States
通讯作者单位
The Shu Chien-Gene Lay Department of Bioengineering and Institute of Engineering in Medicine, University of California, San Diego, La Jolla, CA, USA. ywang283@usc.edu.United States
文献类型
非美国政府资助研究 · 美国 NIH 资助研究
期刊
Nature materials2026 Feb
原文标识
PubMed 41174038 · DOI 10.1038/s41563-025-02391-8